Xtant Medical (NYSEAMERICAN:XTNT) Announces Quarterly Earnings Results

Xtant Medical (NYSEAMERICAN:XTNT) issued its earnings results on Monday. The medical device company reported $0.01 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.02, FiscalAI reports. Xtant Medical had a negative return on equity of 10.12% and a negative net margin of 3.59%.The business had revenue of $27.77 million during the quarter, compared to analyst estimates of $32.70 million. Xtant Medical updated its FY 2025 guidance to EPS.

Xtant Medical Trading Down 0.6%

Xtant Medical stock opened at $0.76 on Wednesday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.16 and a current ratio of 2.47. The stock has a market cap of $105.88 million, a PE ratio of -18.91 and a beta of -0.22. The stock has a 50-day moving average of $0.71 and a two-hundred day moving average of $0.66. Xtant Medical has a one year low of $0.33 and a one year high of $0.95.

Hedge Funds Weigh In On Xtant Medical

Several hedge funds and other institutional investors have recently modified their holdings of XTNT. Jane Street Group LLC purchased a new stake in Xtant Medical during the 2nd quarter worth approximately $26,000. Mink Brook Asset Management LLC lifted its stake in shares of Xtant Medical by 125.8% during the second quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company’s stock worth $81,000 after buying an additional 60,997 shares during the period. Crescent Grove Advisors LLC lifted its stake in shares of Xtant Medical by 94.3% during the second quarter. Crescent Grove Advisors LLC now owns 412,024 shares of the medical device company’s stock worth $304,000 after buying an additional 200,000 shares during the period. Vanguard Group Inc. grew its holdings in shares of Xtant Medical by 4.6% during the third quarter. Vanguard Group Inc. now owns 2,355,671 shares of the medical device company’s stock valued at $1,529,000 after buying an additional 104,159 shares during the last quarter. Finally, AWM Investment Company Inc. acquired a new position in shares of Xtant Medical in the 2nd quarter valued at $4,875,000. 69.33% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, BTIG Research decreased their price objective on Xtant Medical from $2.00 to $1.50 and set a “buy” rating for the company in a report on Tuesday. One investment analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $1.50.

Xtant Medical Company Profile

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.